Abbisko Therapeutics Co, Ltd
Works in Dermatology · Genetic & rare · GI & liver · Musculoskeletal · Oncology · Respiratory
Abbisko Therapeutics Co, Ltd is a clinical trial sponsor. It has 21 active clinical trials with 3,058 planned participants, across 6 therapeutic areas. Since 2021 it has completed 12 trials and stopped 0 early. Its FDA record on file shows compliance actions.
Trial track record · since 2021
FDA record
Recent FDA actions
Pipeline · 21 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Abbisko Therapeutics Co, Ltd
No warning letter naming Abbisko Therapeutics Co, Ltd is on file. FDA has published other compliance actions naming it.
Abbisko Therapeutics Co, Ltd is lead sponsor of 21 active clinical trials on ClinicalTrials.gov, with 3,058 planned participants, in Dermatology, Genetic & rare, GI & liver, Musculoskeletal and other areas. Since 2021 it has completed 12 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Abbisko Therapeutics Co, Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-04.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Abbisko Therapeutics Co, Ltd. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.